BD Board Declares Dividend, Authorizes 10 Million Additional Share Repurchases; BD Completed $250 Million Repurchase to Date in FY26

BD (NYSE: BDX) declared a quarterly cash dividend of $1.05 per common share, payable March 31, 2026, to holders of record on March 10, 2026, equal to an indicated annual dividend of $4.20 per share.

Rhea-AI Summary

BD (NYSE: BDX) declared a quarterly cash dividend of $1.05 per common share, payable March 31, 2026, to holders of record on March 10, 2026, equal to an indicated annual dividend of $4.20 per share. The company has repurchased $250 million of BD stock to date in fiscal 2026. The board also authorized repurchases of up to 10 million additional shares of common stock, to be executed via open market purchases, privately negotiated transactions or other methods. Management will determine the timing, manner, number and value of repurchases at its discretion and subject to market, economic and business considerations.

Positive

• Quarterly dividend of $1.05 declared, payable Mar 31, 2026
• Indicated annual dividend rate of $4.20 per share
• $250 million of stock repurchases completed year-to-date in FY26 and authorization for 10 million additional shares

Negative

• Share repurchases are discretionary; timing and size uncertain and depend on market and business conditions

Argus Jan 28 session

-0.73% close to close Open Argus

Details

News Market Reaction – BDX

On Jan 28, the first trading day after this news, BDX closed 0.73% below the previous close.

Data tracked by StockTitan Argus for the Jan 28 session.

Market Context

This announcement combines income and capital return elements: a $1.05 quarterly dividend (indicated...

Analysis

This announcement combines income and capital return elements: a $1.05 quarterly dividend (indicated $4.20 annual rate), $250 million in buybacks completed so far in fiscal 2026, and authorization to repurchase up to 10 million additional shares. In the past months BD reported record $21.8 billion revenue and $2.2 billion returned to shareholders, while insider activity showed net selling, giving investors multiple data points on capital allocation and governance.

Key Figures

Quarterly dividend: $1.05 per share Annual dividend rate: $4.20 per share Repurchases FY26 to date: $250 million +5 more

Quarterly dividend

$1.05 per share

Declared, payable on March 31, 2026 to holders of record on March 10, 2026

Annual dividend rate

$4.20 per share

Indicated annual dividend rate based on current quarterly dividend

Repurchases FY26 to date

$250 million

BD stock repurchased to date in fiscal 2026

New buyback authorization

10 million shares

Additional BD common shares authorized for repurchase by the board

Record revenue

$21.8 billion

Record fiscal 2025 revenue disclosed in DEF 14A

GAAP EPS

$5.82

Fiscal 2025 GAAP EPS from DEF 14A

Adjusted diluted EPS

$14.40

Record fiscal 2025 adjusted diluted EPS from DEF 14A

Capital returned

$2.2 billion

Capital returned to shareholders via buybacks and dividends in fiscal 2025

Historical Context

5 past events · Latest: Jan 23

5 events

1. Jan 23

   Product platform launch

   24h Move

   -2.1%

   Launch of BD Research Cloud 7.0 with AI-powered panel design tools.

2. Jan 21

   Strategic partnership

   24h Move

   +1.4%

   Expanded collaboration with Ypsomed for large-volume biologics delivery.

3. Jan 15

   Regulatory clearance

   24h Move

   +0.5%

   FDA 510(k) clearance for EnCor EnCompass breast biopsy system.

4. Jan 14

   Leadership change

   24h Move

   +2.9%

   Appointment of a new senior vice president of investor relations.

5. Jan 13

   Capacity investment

   24h Move

   -0.6%

   Announcement of $110M expansion of U.S. syringe and cannula production.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

510(k) clearance, form 144, form 4, 8-k, +4 more

8 terms

510(k) clearance regulatory

"BD received FDA 510(k) clearance for the EnCor EnCompass Breast Biopsy..."

A 510(k) clearance is a U.S. regulatory approval that lets a medical device be sold because it is shown to be substantially similar to an already-legal device; think of it as a passport saying the new product is close enough to a known item to enter the market without a full, lengthy review. For investors, 510(k) clearance signals faster, lower-cost market access and reduced regulatory risk compared with new, untested device pathways, which can materially affect timelines, costs and revenue prospects.

form 144 regulatory

"insider files a Form 144 to sell a small block of shares..."

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

View in glossary

form 4 regulatory

"[Form 4] BECTON DICKINSON & CO Insider Trading Activity"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

View in glossary

8-k regulatory

"[8-K] BECTON DICKINSON & CO Reports Material Event"

An 8-K is a public report companies must file with the U.S. Securities and Exchange Commission to disclose major events or changes that shareholders should know about, such as leadership changes, mergers, financial surprises, or legal developments. It matters to investors because it acts like a breaking-news alert for a company’s health and prospects—providing timely facts that can affect stock value and investment decisions.

View in glossary

def 14a regulatory

"[DEF 14A] BECTON DICKINSON & CO Definitive Proxy Statement"

A Form 14A is a document that companies send to shareholders before important meetings, such as votes on company decisions. It provides detailed information about the topics to be discussed or voted on, helping shareholders make informed choices. This form is essential because it ensures transparency and allows investors to understand what they are approving or rejecting.

rule 10b5-1 financial

"reported transactions were made under a Rule 10b5-1 trading plan..."

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

restricted stock units financial

"The securities to be sold were acquired as restricted stock units..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

reverse morris trust financial

"planned Reverse Morris Trust transaction combining its Biosciences..."

A reverse Morris trust is a tax-efficient deal structure used when a company separates a business unit and immediately combines that unit with another company, allowing the original company’s shareholders to own the merged business. Investors care because it can let companies sell or restructure assets without a big tax bill, affecting shareholder value, ownership percentages, and how quickly the combined business can generate returns—think splitting off a room from your house and having it join a neighbor’s home to avoid a costly property tax.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FRANKLIN LAKES, N.J., Jan. 27, 2026 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.05 per common share, payable on March 31, 2026, to holders of record on March 10, 2026. The indicated annual dividend rate is $4.20 per share.

The company also announced it repurchased $250 million in BD stock to date in fiscal 2026. In addition, the board has authorized the company to repurchase up to 10 million shares of BD common stock in addition to the shares that remain available under the board's previous authorizations in 2021 and 2025. The authorizations provide the company the ability to repurchase shares of its common stock through open market purchases, privately negotiated transactions or other methods. The actual timing, manner, number and value of any shares repurchased will be determined by management at its discretion and will depend on a number of factors, including the market price of BD's common stock, general market and economic conditions, and other business considerations.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. 

Contacts:
Media:	Investors:
Matt Marcus	Shawn Bevec
VP, Public Relations	SVP, Investor Relations
matt.marcus@bd.com	investor.relations@bd.com

 

View original content:https://www.prnewswire.com/news-releases/bd-board-declares-dividend-authorizes-10-million-additional-share-repurchases-bd-completed-250-million-repurchase-to-date-in-fy26-302671512.html

SOURCE BD (Becton, Dickinson and Company)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What dividend did BD (BDX) declare on January 27, 2026?

BD declared a quarterly dividend of $1.05 per share, payable Mar 31, 2026, to holders of record on Mar 10, 2026.

What is BD's indicated annual dividend rate after the Jan 27, 2026 declaration?

The indicated annual dividend rate is $4.20 per share.

How much has BD (BDX) repurchased in fiscal 2026 so far?

BD has repurchased $250 million of its common stock to date in fiscal 2026.

How many additional BD (BDX) shares did the board authorize on Jan 27, 2026?

The board authorized repurchases of up to 10 million additional shares of common stock.

When will BD's Mar 31, 2026 dividend be paid and who is eligible?

The dividend will be paid on Mar 31, 2026 to shareholders of record as of Mar 10, 2026.

How will BD execute the newly authorized share repurchases?

Repurchases may occur via open market purchases, privately negotiated transactions, or other methods, at management's discretion.